RVTY

Based on Revvity, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

What does Revvity do?

Revvity provides instruments, reagents, software, and services across two segments: Discovery & Analytical Solutions — serving life sciences, environmental, and industrial markets — and Diagnostics, which focuses on early detection of genetic disorders and infectious diseases. The company's tools are used by researchers, clinicians, and industrial operators worldwide.

Does RVTY pay dividends?

Yes, Revvity pays a regular dividend. This is relatively uncommon among life sciences companies, many of which prioritize reinvestment over distributions. Investors should review the current dividend details on Revvity's investor relations page, as amounts and schedules can change.

When does RVTY report earnings?

Revvity reports on a quarterly cadence, as is standard for US-listed companies. The company does not pre-announce exact dates far in advance. Check Revvity's investor relations page or financial calendar services for the most current schedule.

Is RVTY a good stock to buy?

UQS Score rates RVTY as Below Average, reflecting Weak ratings across Quality, Moat, Growth, and Risk pillars. The Valuation pillar is rated Good, which may appeal to value-focused investors. Whether the stock fits your portfolio depends on your risk tolerance and investment goals — the full pillar breakdown is available to Pro members.

Is RVTY overvalued?

The UQS Valuation pillar for RVTY is rated Good, suggesting the stock is not trading at an obviously stretched premium relative to its fundamentals. However, a reasonable valuation alone does not offset the Weak ratings across the other four pillars. View the complete valuation metrics with a UQS Pro account.

How does RVTY compare to its competitors?

Revvity competes with Guardant Health in genomic diagnostics, ICON in contract research services, and Charles River Laboratories in preclinical research support. Each competitor has a more focused business model, while Revvity's breadth spans instruments, reagents, environmental analytics, and genetic screening across multiple end markets.

What is RVTY's market cap bracket?

Revvity is classified as a large-cap company. This places it among established, well-recognized healthcare businesses with significant operational scale, though large-cap status alone does not indicate financial strength or quality — as reflected in RVTY's Below Average UQS Score.

Who founded Revvity?

Revvity traces its origins to 1965. The company has undergone significant transformation over the decades, including a major rebranding from PerkinElmer to Revvity in 2023 following a portfolio restructuring. Detailed founding history is publicly available through the company's official communications.

Is RVTY a long-term quality indicator?

From a long-term quality perspective, RVTY's UQS profile raises caution. Weak ratings across Quality, Moat, Growth, and Risk pillars suggest the company has not yet demonstrated the durable competitive advantages and consistent financial performance that typically characterize high-quality long-term holdings. The Good Valuation rating provides some context but does not resolve those structural concerns.

What is the main competitive advantage of Revvity?

Revvity's breadth across diagnostics, life sciences research, and industrial analytics gives it exposure to multiple end markets. Its established presence in newborn and prenatal screening — a regulated, recurring-demand segment — provides some structural stability. However, the Weak Moat pillar rating suggests these advantages have not translated into a clearly defensible competitive position.

What sector does RVTY belong to?

Revvity operates in the Healthcare sector, specifically spanning diagnostics and life sciences tools. Investors tracking this space can explore related companies and sector-level quality rankings on UQS Score's [sector pages](/sector/healthcare).

Is RVTY a growth stock or value stock?

Based on UQS pillar labels, RVTY does not fit neatly into either category. The Growth pillar is rated Weak, making it difficult to classify as a growth stock. The Valuation pillar is rated Good, which leans toward value territory — but a low valuation driven by weak fundamentals is different from a classic value opportunity.

Revvity, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.

Revvity, Inc. faces growth headwinds with declining or stagnant revenue trends.

Revvity, Inc. has some risk factors including moderate leverage or solvency concerns.

Revvity, Inc. trades at a reasonable valuation with decent earnings yield and FCF multiples.

Revvity, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for RVTY.

The UQS (Unified Quality Score) for Revvity, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses Revvity, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether Revvity, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.